07/07/2026 ITM‑11 significantly outperforms everolimus in advanced GEP‑NETs with superior efficacy and safety ITM‑11 significantly outperforms everolimus in advanced GEP‑NETs with superior efficacy and safety (Ref) ITM announced that primary results from its Phase 3 COMPETE trial were published in The Lancet, showing that investigational ¹⁷⁷Lu-edotreotide (ITM-11; SSTR2-targeted peptide receptor radionuclide therapy) significantly improved progression-free survival and respon